🎉 M&A multiples are live!
Check it out!

CARISMA Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for CARISMA Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

CARISMA Therapeutics Overview

About CARISMA Therapeutics

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.


Founded

2008

HQ

United States of America
Employees

107

Website

carismatx.com

Financials

LTM Revenue $21.2M

LTM EBITDA n/a

EV

-$6.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

CARISMA Therapeutics Financials

CARISMA Therapeutics has a last 12-month revenue of $21.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, CARISMA Therapeutics achieved revenue of $14.9M and an EBITDA of -$85.9M.

CARISMA Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See CARISMA Therapeutics valuation multiples based on analyst estimates

CARISMA Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $14.9M $21.4M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$85.9M n/a XXX XXX XXX
EBITDA Margin -576% NaN% XXX XXX XXX
Net Profit -$40.8M -$61.2M XXX XXX XXX
Net Margin -273% -286% XXX XXX XXX
Net Debt n/a $9.5M XXX XXX XXX

Financial data powered by Morningstar, Inc.

CARISMA Therapeutics Stock Performance

As of March 17, 2025, CARISMA Therapeutics's stock price is $0.

CARISMA Therapeutics has current market cap of $17.2M, and EV of -$6.4M.

See CARISMA Therapeutics trading valuation data

CARISMA Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$6.4M $17.2M XXX XXX XXX XXX $-1.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

CARISMA Therapeutics Valuation Multiples

As of March 17, 2025, CARISMA Therapeutics has market cap of $17.2M and EV of -$6.4M.

CARISMA Therapeutics's trades at -0.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate CARISMA Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for CARISMA Therapeutics and 10K+ public comps

CARISMA Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$6.4M XXX XXX XXX
EV/Revenue -0.3x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -0.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CARISMA Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

CARISMA Therapeutics Valuation Multiples

CARISMA Therapeutics's NTM/LTM revenue growth is -14%

CARISMA Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, CARISMA Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate CARISMA Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for CARISMA Therapeutics and other 10K+ public comps

CARISMA Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 44% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 198% XXX XXX XXX XXX
R&D Expenses to Revenue 497% XXX XXX XXX XXX
Opex to Revenue 695% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

CARISMA Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

CARISMA Therapeutics M&A and Investment Activity

CARISMA Therapeutics acquired  XXX companies to date.

Last acquisition by CARISMA Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . CARISMA Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by CARISMA Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About CARISMA Therapeutics

When was CARISMA Therapeutics founded? CARISMA Therapeutics was founded in 2008.
Where is CARISMA Therapeutics headquartered? CARISMA Therapeutics is headquartered in United States of America.
How many employees does CARISMA Therapeutics have? As of today, CARISMA Therapeutics has 107 employees.
Who is the CEO of CARISMA Therapeutics? CARISMA Therapeutics's CEO is Mr. Steven Kelly.
Is CARISMA Therapeutics publicy listed? Yes, CARISMA Therapeutics is a public company listed on NAS.
What is the stock symbol of CARISMA Therapeutics? CARISMA Therapeutics trades under CARM ticker.
When did CARISMA Therapeutics go public? CARISMA Therapeutics went public in 2023.
Who are competitors of CARISMA Therapeutics? Similar companies to CARISMA Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of CARISMA Therapeutics? CARISMA Therapeutics's current market cap is $17.2M
What is the current revenue of CARISMA Therapeutics? CARISMA Therapeutics's last 12-month revenue is $21.2M.
What is the current EV/Revenue multiple of CARISMA Therapeutics? Current revenue multiple of CARISMA Therapeutics is -0.3x.
What is the current revenue growth of CARISMA Therapeutics? CARISMA Therapeutics revenue growth between 2023 and 2024 was 44%.
Is CARISMA Therapeutics profitable? Yes, CARISMA Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.